Neurocrine Biosciences (NBIX) Expected to Announce Quarterly Earnings on Tuesday

Neurocrine Biosciences (NASDAQ:NBIX) will likely be announcing its Q3 2025 results after the market closes on Tuesday, October 28th. Analysts expect the company to announce earnings of $1.55 per share and revenue of $746.6050 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 4:30 PM ET.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.98 by $0.08. The firm had revenue of $687.50 million for the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The business’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.63 EPS. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $141.33 on Tuesday. The company has a market capitalization of $14.02 billion, a price-to-earnings ratio of 41.81, a P/E/G ratio of 1.01 and a beta of 0.21. The business’s 50-day moving average is $139.00 and its 200-day moving average is $126.56. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $154.61.

Insider Activity

In related news, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the sale, the director owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Several large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its position in Neurocrine Biosciences by 40.5% during the second quarter. AQR Capital Management LLC now owns 1,510,015 shares of the company’s stock valued at $189,794,000 after purchasing an additional 435,385 shares in the last quarter. Bank of America Corp DE raised its position in Neurocrine Biosciences by 16.4% during the second quarter. Bank of America Corp DE now owns 653,011 shares of the company’s stock valued at $82,077,000 after purchasing an additional 91,942 shares in the last quarter. Alliancebernstein L.P. raised its position in Neurocrine Biosciences by 1.4% during the second quarter. Alliancebernstein L.P. now owns 584,431 shares of the company’s stock valued at $73,457,000 after purchasing an additional 8,259 shares in the last quarter. Ameriprise Financial Inc. raised its position in Neurocrine Biosciences by 40.4% during the second quarter. Ameriprise Financial Inc. now owns 443,245 shares of the company’s stock valued at $55,711,000 after purchasing an additional 127,535 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Neurocrine Biosciences during the second quarter valued at about $42,933,000. Institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. UBS Group boosted their price objective on Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Guggenheim boosted their price objective on Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Morgan Stanley boosted their price objective on Neurocrine Biosciences from $163.00 to $168.00 and gave the stock an “overweight” rating in a report on Monday. Truist Financial assumed coverage on Neurocrine Biosciences in a report on Monday, July 21st. They set a “buy” rating and a $163.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $140.00 to $145.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $163.72.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.